Department of Cardiology Gifu University Graduate School of Medicine Gifu Japan.
Cardiology Gifu Municipal Hospital Gifu Japan.
Pharmacol Res Perspect. 2018 Dec 21;7(1):e00451. doi: 10.1002/prp2.451. eCollection 2019 Feb.
We investigated whether combination therapy of G-CSF and erythropoietin (EPO)-liposome with Siaryl Lewis X (SLX) is more cardioprotective than G-CSF or EPO-liposome with SLX alone. For the purpose of generating myocardial infarction (MI), rabbits underwent 30 minutes of coronary occlusion and 14 days of reperfusion. We administered saline (control group, i.v.,), G-CSF (G group, 10 μg/kg/day × 5 days, i.c., starting at 24 hours after reperfusion), EPO-liposome with SLX (LE group, i.v., 2500 IU/kg EPO containing liposome with SLX, immediately after reperfusion), and G-CSF + EPO-liposome with SLX (LE + G group) to the rabbits. The MI size was the smallest in the LE+G group (14.7 ± 0.8%), and smaller in the G group (22.4 ± 1.5%) and LE group (18.5 ± 1.1%) than in the control group (27.8 ± 1.5%). Compared with the control group, the cardiac function and remodeling of the G, LE, and LE + G groups were improved, and LE + G group tended to show the best improvement. The number of CD31-positive microvessels was the greatest in the LE + G group, greater in the G and LE groups than in the control group. Higher expressions of phosphorylated (p)-Akt and p-ERK were observed in the ischemic area of the LE and LE + G groups. The number of CD34/CXCR4 cells was significantly higher in the G and LE + G groups. The cardiac SDF-1 was more expressed in the G and LE + G groups. In conclusion, Post-MI combination therapy with G-CSF and EPO-liposome with SLX is more cardioprotective than G-CSF or EPO-liposome with SLX alone through EPCs mobilization, neovascularization, and activation of prosurvival signals.
我们研究了粒细胞集落刺激因子(G-CSF)和红细胞生成素(EPO)-脂质体联合 SLX 是否比 G-CSF 或 EPO-脂质体联合 SLX 单独治疗更具心脏保护作用。为了产生心肌梗死(MI),兔子经历了 30 分钟的冠状动脉阻塞和 14 天的再灌注。我们给予生理盐水(对照组,静脉注射)、G-CSF(G 组,每天 10μg/kg,×5 天,再灌注后 24 小时开始,皮内注射)、SLX 的 EPO-脂质体(LE 组,静脉注射,含 SLX 的脂质体 2500IU/kg,再灌注后立即)和 G-CSF+SLX 的 EPO-脂质体(LE+G 组)。LE+G 组的 MI 面积最小(14.7±0.8%),G 组(22.4±1.5%)和 LE 组(18.5±1.1%)比对照组(27.8±1.5%)小。与对照组相比,G、LE 和 LE+G 组的心脏功能和重构得到改善,LE+G 组的改善趋势更为明显。LE+G 组 CD31 阳性微血管数量最多,G 组和 LE 组比对照组多。LE 和 LE+G 组缺血区磷酸化(p)-Akt 和 p-ERK 的表达更高。G 组和 LE+G 组的 CD34/CXCR4 细胞数量明显增加。G 组和 LE+G 组的心脏 SDF-1 表达更多。总之,G-CSF 和 EPO-脂质体联合 SLX 治疗后的心肌梗死后联合治疗比 G-CSF 或 EPO-脂质体联合 SLX 单独治疗更具心脏保护作用,通过动员 EPCs、血管生成和激活生存信号。